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Abstract
Background: Classic Kaposi’s sarcoma (CKS) is a rare disease likely associated with human herpes virus 8 (HHV-8)
infection, and occurs predominantly in Jewish, Mediterranean and middle eastern men .There is a dearth of data in
Moroccan patients with CKS regarding epidemiology, clinical characteristics and outcomes. This report examines a
cohort of patients with CKS evaluated at the national institute of oncology over 11-year period.
Methods: A retrospective analysis of patients referred to the national institute of oncology with classical Kaposi
sarcoma, between January 1998 and February 2008, was performed. Reviewed information included demographics,
clinical and pathological staging, death or last follow-up.
Results: During the study period, 56 patients with a diagnosis of CKS have been referred to our hospital. There
were 11(19,7%) females and 45 (80,3%) males (male-to-female ratio: 4:1). Mean age at diagnosis was 61,7 ± 15
(range: 15- 86 years). Nodules and/or plaques were the most frequent type of lesion. The most common location
was the lower limbs, particularly the distal lower extremity (90%). In addition to skin involvement, visceral spread
was evident in 9 cases. The most common visceral involvement sites were lymph nodes (44%), lung (22%), and
gastrointestinal tract (22%). Associated lymphoedema was seen in 24 (42%) of the patients. There were 18 stage I
patients (32,14%), 8: stage II (14,28%), 21 stage III(37,5%) and 9 stage IV (16,07%). A second primary malignancy was
diagnosed in 6 cases (10,7%), none of the reticuloendothelial system.
With a median follow-up of 45 months, 38 (67,8) patients are alive, of whom 25 (65,78%) patients with stable
disease, five with progressive disease currently under systemic chemotherapy and 8(21,05%) are alive and free of
disease, over a mean interval of 5 years.
Conclusion: This is the largest reported series in our context. In Morocco, CKS exhibits some special characteristics
including a disseminated skin disease at diagnosis especially in men, a more common visceral or lymph node
involvement and a less frequent association with second malignancies.
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Background
Classic Kaposi’s sarcoma (CKS) represents a complex
angioproliferative disease characterized by the appear-
ance of spindle-shaped cells. [1].
It was first described by Moritz Kaposi in Vienna in
1872, as a rare and indolent angioproliferative neoplasm,
mainly present as a skin lesion [2]. It occurs predomi-
nantly in elderly people, particularly men from Eastern
Europe and Mediterranean region. The incidence of
CKS varies greatly with ethnic and geographic factors.
The discovery of Human Herpes virus 8 (HHV-8), also
known as Kaposi’s sarcoma-associated herpesvirus
(KSHV) improved our knowledge of the pathogenesis of
Kaposi’s sarcoma (KS). HHV-8 can be found in all epi-
demiological and histological forms of KS [3] and can
directly be detected in spindle cells [4].
Tumor lesions are characterized by slow progression,
purple macules on the distal portion of the limbs. This
lesions could acquire nodular characteristics when the
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occur in more advanced forms.
There is a lack of data in Moroccan patients with CKS
regarding clinical features, prognosis, and outcome. The
primary aim of this analysis is to outline the clinico-epi-
demiological profile and outcomes of patients with CKS
in the National Institute of Oncology
Methods
A retrospective analysis of patients referred to the
National Institute of Oncology, Rabat, Morocco between
January 1998 and February 2008 with a diagnosis of
CKS was performed. Patients were identified from the
institution tumor registry. KS diagnosis was clinically
suspected and histologically confirmed. Serum samples
from all patients have been tested for antibodies to HIV,
using ELISA and Western Blot. HIV seropositive indivi-
duals have been excluded, as well as patients who had
received immunosuppressive therapy prior to KS devel-
opment. Data were collected from the patients’ medical
files and the following parameters were recorded: gen-
der, origin, age at diagnosis, anatomic distribution (size,
location, multicentricity, immunocompromised condi-
tions, second malignancies, clinical course, and date of
death or last follow-up if date of death unknown).
T h ed a t eo fd i a g n o s i sw a sd e f i n e da st h ed a t eo f
biopsy. All patients underwent physical examination,
haematological and biochemical analysis, and chest
radiography. When clinically indicated, gastrointestinal
endoscopy, abdominal ultrasound or computerized
tomography (CT) scan were done. HHV-8 antibodies
were identified in only 5 patients. The HHV-8 serology
was not realized in our institution before 2007. Con-
cerning HHV-8 antibody identification, an immuno-
fluorescence assay was used. This is a commercially
available test (Kit Biotrin HHV-8-IgG-IFA), using the
indirect immunofluorescent method of antibody detec-
tion and titre determination, providing both qualitative
and quantitative results to the laboratory. Patient sam-
ples are incubated with HHV-8 antigen, which has been
stabilised on a glass slide. If HHV-8 IgG antibodies are
present in the sample, a stable complex is formed
between the antibody and the antigen on the slide.
Bound HHV-8 IgG antibody is then reacted with a
fluorescein conjugated goat anti-human IgG and this
complex is visualised with the aid of a fluorescence
microscope.
Unlike AIDS-associated KS, CKS has no universally
accepted stage classification. In medical files, stage of
the disease were not assessed but can be deducted from
the dermatological examination. A recently proposed
staging system is often followed, which is based on
objective criteria that more closely follow the clinical
variability of CKS; to assess the severity of the CKS, the
new staging system was used retrospectively, based on
objective criteria and the follow up of clinical variability
of CKS. It describes four stages (I-IV) based on skin
lesions, their localization, the presence or absence of
complications and visceral involvement [5].
Follow-up was arranged as a control visit 1 month
after the end of treatment, then four visits in a year
(each 3 month) for 2 years and then two visits each a
year.
Statistical analysis
SPSS13.0 software was used for statistical analysis.
Descriptive of clinical data were expressed in percentage
or median or mean ± SD. Age and sex were compared
between the two groups by stage (I-II vs III- IV) using a
T test for means and c
2 statistic for frequencies.
Consent and statement of ethical approval
As the treatment of each patient was decided by the
medical staff of the centre, oral consent was obtained
from the subjects and was approved by the institutional
review boards of the National Institute of Oncology,
Cancer Centre in Rabat. This study was approved by the
institutional review boards of National Institute of
Oncology, in Rabat.
Results
Patients’ characteristics
Fifty six patients were identified to have a diagnosis of
CKS between January 1998 and February 2008. A mean
of five new patients was diagnosed each year. There
were 11(%) females and 43 (%) males (male-to-female
ratio: 4:1). Mean age at diagnosis was 61,7 ± 15 (range:
15- 86 years).
The median duration to consultation after the first
appearance of lesions was 12 months (range 1-240
months). All patients were North African origin but no
ethnic characteristic, especially Jewish, were identified.
Thirteen percent of patients were smokers. Non-insu-
lin dependant diabetes mellitus was found in 2 cases
(3,9%). Prostatic adenocarcinoma was diagnosed in 2
patients, a lung cancer in 3 patients and a colic cancer
in one patient. No other second primary malignancies
especially related to the lymphoreticular system was
detected. No familial cases of Kaposi’ss a r c o m aw e r e
found.
Clinical features and location of lesions
The clinical pattern of KS in our patients was character-
ized by its extreme variability and represented all stages
of Kaposi Sarcoma: patch (n = 2; 3,5%), plaque (n =17;
30%) and one with ulceration nodular lesions (n= 21;
37%) and 18 with multinodularity, papulonodular (n =
3; 5%) and maculonodular (n = 13; 23%). The nodular
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cases. Lymphedema was present in 24 patients (42%).
Lower limbs were involved in 50 (89,5%) patients, in
22 of whom the disease was confined to this area. The
lesions were developed on both lower and upper extre-
mities in 25(44,6%) subjects. Twelve of these concerned
other areas of the body, in particular head and trunk
were involved as well. Penis lesions were found in five
cases. The lesions were disseminated throughout the
body in 8 patients. In addition to skin involvement, visc-
eral spread was evident in 9 cases. The most common
visceral involvement sites were lymph nodes (44%), lung
(22%), and gastrointestinal tract (22%). HHV-8 serology
realized in five patients was positive. Patients’ character-
istics are summarized in Table 1.
Twenty seven patients were classified in stage I-II (18
in stage I and 9 in stage II) and 29 in stage III- IV
(Table 2). Among those in stage I-II, 70% were men,
with a mean (SD) age of 60,7 (16,87) years. The
corresponding figures for those in stage IV were 96%
and 62,7 (14,05) years, respectively. Mean age did not
differ significantly by clinical stage (p = 0,59). However,
men had significantly more advanced stages than
women (P = 0.002) (table 2).
Clinical course
Over a follow-up period ranging from 10 to 132
months, with a median of 45 months, 7 (12%) of the
CKS patients died of other medical conditions, particu-
larly cardiovascular diseases, two (3,5%) of other malig-
nancies, three (5,3%) of treatment-related complications
and six (10,7%) from widespread visceral CKS. Thirty
eight patients (67%) are alive, of whom 25 with stable
disease, five with progressive disease currently under
systemic chemotherapy, and 8 are alive and free of dis-
ease, over a mean interval of 5 years.
Discussion
Kaposi Sarcoma is a solitary or multifocal lymphatic
tumor, initially described as Classic Kaposi Sarcoma
almost 140 years ago, in elderly men of Middle Eastern
and Mediterranean descent [6,7]. No recent report has
evaluated the demographics and clinical presentations
of CKS patients in Morocco. The current study repre-
sents a large retrospective review of 56 patients with a
diagnosis of CKS seen at our institution over 11-year
period (1998-2008) and is to our knowledge the largest
series in our context focusing on this particular
population.
Most of demographic and clinical features of our
study group are not totally in accordance with previous
findings in the literature.
As the analysis of our results indicates, CKS in Mor-
occo exhibits some special clinico-epidemiological char-
acteristics including nodular lesions as first presentation,
a more frequent association with lymphedema, dissemi-
nated skin lesions at diagnosis, unusual visceral or
lymph node involvement and rare coexistence of second
primary neoplasm.
The National institute of oncology, Rabat, is the most
important cancer center in Morocco, to which are
Table 1 Patients’ characteristics
Characteristics N(%)
Age at diagnosis
Mean ± SD 61,7 ± 15,2
Range 15-86
Gender
Male 45 (80,3%)
Female 11 (19,7%)
Location of lesion
Skin 56 (100%)
Extracutaneous 9 (16%)
Second primary malignancies
Present 2 (3,5%)
Absent 54 (96,5%)
Stage at diagnosis
I 18 (32, 1%)
II 9 (16%)
III 20 (35, 7%)
IV 9 (16, 2%)
Distribution of lesions.
Lower limbs 50
Both upper and lower extremities 21
Trunk 8
Visceral organs 9
Head and Neck 9
Genital organs 5
Type of lesions
Patch 2
Plaques 17
Nodules 21
Maculonodular 3
Papulonodular 13
Table 2 Staging of the Studied Population
Staging of disease
Characteristics I-II III-IV
No. (%) of patients 27(48%) 29 (52%)
Sex, No. (%)*
Male 17 (70%) 28 (96%)
Female 10 (30%) 1 (4%)
Age, y, mean (SD)† 60,7 (16,87) 62,7 (14,05)
*P = .002, stage I-II vs stage III-IV.
†P = .59 stage I-II vs stage II- IV
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country.
In Morocco, we do not possess a national cancer reg-
istry, however the local cancer registry of Rabat in 2005,
reported a standardized incidence rate of 0,39/100000
habitants. CKS is not uncommon in Morocco, with
sporadic cases all over the country. Geographical distri-
bution of CKS according to the region of origin sup-
poses that the disease is more common in northern
Morocco. However statistical data regarding the place of
birth in general Moroccan population are lacking and
no genetic or environnemental factors can be defined.
The incidence of CKS varies greatly with ethnic and
geographic factors. The predisposition of Jews has been
described in the literature. In Israel, rates of CKS of
2.07 in men and 0.75 in women per 100,000 were calcu-
lated [8]. The risk for Jews to develop CKS is 10 times
higher than for non-Jews [9]. CKS is rare in North
America and North Europe. Low rates were reported in
England and Wales as well as in Denmark; intermediate
rates were reported in Sweden, whereas higher rates
were reported in Italy [10]. The highest incidence rates
in Europe were reported in two Mediterranean Italian
islands: Sardinia and Sicily. At the National Institute of
Oncology, Rabat, CKS accounts 0,1% of all new cases of
cancer with a mean of 5 cases diagnosed each year.
The identification of HHV-8 as the causative agent of
KS has greatly enhanced our understanding of the
pathogenetic events that lead to the development of this
tumor [11]. A strong direct correlation between HHV-8
prevalence and CKS incidence was documented. HHV-8
now is known to be the primary cause of all types of KS
[12], but CKS occurs in only a small fraction of HHV-8
infected people. In the Mediterranean area, classical KS
develops annually in only 0.03% of the HHV-8 infected
men older than 50 years and in 0.01%-0.02% of the
HHV-8-infected women older than 50 years [12]. Var-
ious cofactors have been implicated in the pathogenesis
of KS, including genetic susceptibility, immunologic
alterations, and endocrine factors [13,14]. It has been
hypothesized that the abundant expression of various
proinflammatory cytokines in early KS lesions may cre-
ate an immunologic microenvironment that stimulates
the growth of HHV-8 and promotes the development of
clinical lesions.[15,16].
One study is available about HHV-8 frequency among
CKS patients in Morocco. Kassemi et al reported the
seroprevalence of anti-HHV8 antibodies in 2 groups of
HIV negative Moroccan patients. Among the 26
patients, 24 (92%) presented with anti-HHV8 antibodies,
whereas the 26 donors were seronegative for HHV-8
[17]. In our series, the seroprevalence of anti-HHV8
were not explored. However the serology of anti HHV-8
was done in 5 patients in which it was positive.
The mean age of onset in our series is mainly in
accordance to other similar reports [18] . In fact, CKS is
ad i s e a s eo ft h ee l d e r l yw i t ham e d i a na g ea td i a g n o s i s
reported variously from 50 to 80 years [19,20]. Popula-
tion-based incidence studies from the United States and
Europe reported that the median age at time of diagno-
sis is the seventh decade of life and only 4-8% of cases
were reported in individuals younger than 50 years
[10,21]. In the current study, 10 patients were younger
than 50 years and the youngest patient was a 15 years
old. Worldwide, only sporadic cases occurring before
the age of 30 years and occasional cases of CKS have
been reported in children [22]. In Israel the median age
at onset of CKS is 67 years (range,11-91 years) with no
significant variation noted between people from different
countries of origin [23,24]. From 1961 until 1989, 13%
of the cases of CKS reported in Israel involved people
age, 55 years; 0.3% were age, 15 years, with no variation
reported during the period.
Interestingly, 90% women in our study were of post-
menopausal age (49-84 years), providing additional sup-
port to the speculation that female sex hormones may
act prophylactically to CKS development [18].
CKS has an overwhelming male predominance, with a
male-to-female ratio of approximately 10:1 to 15:1
[10,18]. However, in more recent studies, the sex ratio is
much lower: 8:1 in Colombia [25], and 3:1 in Italy [26].
The 4:1 male-to-female ratio found in our study has
been reported previously [10,27].
Cutaneous KS is often first evident as discrete erythe-
matous or violaceous bilaterally symmetric patches,
most commonly on the lower extremities. A study of
Sardinian CKS found this initial lower extremity location
evident in 155 of 200 patients [28]. Patches may evolve
into plaques and nodules. Nodules and/or plaques were
the most common type of lesion in our series.
Associated lymphedema, especially of the feet, is not
uncommon and it occurred particularly in a high pro-
portion (42%) of our patients.
KS is a multicentric neoplasm frequently evident as a
multiple vascular cutaneous and mucosal nodules
[29,30]. Lesions may be limited to skin or sometimes
arises to oral cavity, lymph nodes, or viscera in 10-15%
[31]. The gastrointestinal tract is the most common
extracutaneous site of involvement. An endoscopic
upper gastrointestinal tract evaluation of 87 Greek CKS
patients showed that 71 (81.6%) had gastrointestinal
lesions [32]. Other visceral organs that may be affected
include liver, heart and lung [23,33].
Our study reveals more locations in upper extremities,
lymph nodes, and visceral sites than previously reported
for CKS [33,34]. Unusual sites, as seen in 14 of our
patients, include penis, ear, mouth, eyelids, conjunctiva,
and nose. They are often associated with poor prognosis
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the penis in the current study may relate to an aggres-
sive form of the disease.
P r o g n o s i sa p p e a r st oc o r r e l a t ew i t ht h ed e g r e eo f
immunosuppression and older age among classic KS
patients[35,36]. Localized nodular KS has the best prog-
nosis, with few deaths directly attributable to KS. Clini-
cal classification of KS may be the best prognosticator,
comparing localized nodular disease, locally aggressive
disease, and generalized KS.
Several staging systems have been proposed for the
classification of CKS [37,38]. A recently proposed sta-
ging system is often followed, which is based on objec-
tive criteria that more closely follow the clinical
variability of CKS, and thereby makes therapeutic
choices easier. We elected this staging classification
because it allows a better distinction between early
(skin-localized) and advanced (disseminated) CKS.
CKS by itself is rarely the cause for the patient’s
demise. In the current study CKS is more aggressive
than reported in the literature, with 29 (51,7%) having
multicentric disease and classified in stage III and IV
and 16% with widespread disseminated disease. Further-
more, the proportion of patients with systemic involve-
ment in our cohort was slightly higher to that seen in
other series of patients with CKS, ranging from 4% to
10% of patients.[10,36]. Also, in this work, we found
that men were more likely to have advanced stage at
diagnosis. Such observations were not previously noted.
For example, Stratigos and al reported a series of Sixty-
eight patients. Mean age and sex did not differ signifi-
cantly by clinical stage (I-II vs IV)
It is not a novel observation that CKS is associated
with other primary malignancies, often of the reticu-
loendothelial system, that may precede, coincide with or
follow the occurrence of CKS [39]. CKS is reportedly
more commonly a primary than a secondary neoplasm
[34]. However, information was obtained in several
cases indicating CKS arose subsequent to other malig-
nancy, offering the suggestion of a common etiology.
The current study found that only 10,7% of CKS
patients with complete follow-up data available had
associated a second primary malignancy, a lower occur-
rence than previously reported in the literature, 9-42%.
[33,40-42]. This lower frequency of second primary
malignancies is similar to the 18% found in a previous
study on Israeli patients by Feurman and al [43].
The association between aggressive clinical course of
CKS and immunosuppression has previously been sug-
gested. The immunological dysfunction underlying CKS
i su n k n o w na n dm a yr e s u l tf r o ma d v a n c e da g eo r
chronic infection [19]. Its induction by immunosuppres-
sive therapy and its subsequent regression on removal
of immunosuppression provided early clinical
recognition of the reversibility of CKS. However, none
of our patients reported an immunologic dysfunction
supporting the previous report of an immunological
etiology of CKS [44].
Diabetes mellitus seems to occur more frequently
among CKS patients than in the general population
[31]. The high frequency of non-insulin dependent dia-
betes mellitus has been reported repeatedly among
American [45] and Israeli [43] subjects but was not
found in subjects with endemic form of CKS [46]. The
frequency 3,9% of non-insulin dependent diabetes melli-
tus in our series is lower than reported in the literature.
Only a small number of familial cases of CKS have
been reported[35,46,47]. Among Ninety CKS subjects
d e s c r i b e db yD iG i o v a n a[ 3 5 ] ,o n l yo n ew a sf a m i l i a l .
Similarly, in a series of 56 CKS patients from north-east
Sardinia, no familial cases were reported.[48]
Conclusion
CKS in Morocco is predominantly a male disease which
exhibits some special characteristics, including dissemi-
nated skin disease at diagnosis, often accompanied by
lymphedema, more common visceral or lymph node
involvement and a less frequent association with second
malignancies. Although disease may persist, Classic
K a p o s iS a r c o m ab yi t s e l fi sr a r e l yt h ec a u s eo ft h e
patient’s death. Extensive epidemiologic studies in Mor-
occo are required.
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